@CONFERENCE\{IMM2007-05224, author = "Y. Kato and D. A. Holm and B. Okollie and D. Artemov", title = "Visualization of Drug Distribution in Brain Tumors in Mice by {MRSI}", year = "2007", month = "apr", booktitle = "Proc 98th American Association for Cancer Research Annual Meeting", volume = "", series = "", editor = "", publisher = "", organization = "", address = "", url = "http://www2.compute.dtu.dk/pubdb/pubs/5224-full.html", abstract = "Purpose: In mouse brain tumor models, little uptake of high molecular weight (MW) {MR} contrast agents is detected due to blood-brain barrier (BBB) and blood-brain tumor barrier (BTB). We have tested i) a combination of bolus tracking and dynamic contrast enhanced (DCE) {MRI} following injection of low {MW} contrast agent, GdDTPA, to extract vascular parameters of the tumor, and ii) indirect detection 13C magnetic resonance spectroscopic imaging (MRSI) in brain tumor-bearing mice following injection of 13C-labeled anticancer agent, temozolomide [13C]TMZ. Methods: For {DCE} and bolus tracking experiments, Saturation-recovery T1 (TE/TR=1.245/500ms, {TD}=0.25, 0.{5,} 1s, slice thickness=2mm) and {FLASH} T2* (TE/TR=3.5/500ms, slice thickness=2mm) sequences were acquired. For inverse-detection {MRSI} experiments, heteronuclear multiple-quantum coherence (HMQC) technique (TE/TR=15/1500ms, 8\&\#61620;8 voxels, slice thickness=4mm) was used with {WALTZ-}16 decoupling in 13C channel. Prior to {MRI}/{MRSI} experiments with mice bearing orthotopic U87MG human glioblastoma xenografts, the mouse tail vein was catheterized for injection of GdDTPA (1:2 dilution of Magnevist®) and an intraperitoneal catheter was inserted for i.p. administration of [13C]TMZ. Experimental parameters were optimized with a methanol phantom. All {MR} studies were carried out on a horizontal bore Bruker Biospec 9.{4T} spectrometer. {MR} data were analyzed using in-house software written in the {IDL}™ and MatLab™ programming environment." }